SAM
MRNA icon

Silvercrest Asset Management’s Moderna MRNA Stock Holding History

Silvercrest Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,880
Closed -$223K – 820
2024
Q2 		$223K Sell
1,880
-1,240
-40% -$157K ﹤0.01% 855
2024
Q1 		$332K Sell
3,120
-4
-0.1% -$403 ﹤0.01% 787
2023
Q4 		$311K Buy
3,124
+840
+37% +$70.7K ﹤0.01% 744
2023
Q3 		$236K Buy
+2,284
New +$255K ﹤0.01% 778
2022
Q1 		– Sell
-1,230
Closed -$312K – 869
2021
Q4 		$312K Buy
1,230
+30
+3% +$8.77K ﹤0.01% 735
2021
Q3 		$462K Hold
1,200
– – ﹤0.01% 689
2021
Q2 		$282K Buy
+1,200
New +$214K ﹤0.01% 764

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Silvercrest Asset Management's MRNA Position: Q3 2024 in Review

Silvercrest Asset Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,880 shares — an estimated $223K sold.

Silvercrest Asset Management first reported a position in MRNA in Q2 2021 and held it in 7 quarters. The position peaked at $462K in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Silvercrest Asset Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Silvercrest Asset Management sold 1,880 Moderna shares in Q3 2024, an estimated $223K.
  • Silvercrest Asset Management first reported a position in Moderna in Q2 2021 and held it in 7 quarters.
  • Silvercrest Asset Management's Moderna position peaked at $462K in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Silvercrest Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.